Automated image-based biomarker computation tools for diabetic retinopathy

摘要 在这个项目中，我们提出了EyeMark，一个先进的纵向图像分析系统， 用于自动计算糖尿病视网膜病变（DR）生物标志物的分析工具， 视网膜眼底图像具体来说，我们已经开发了计算微安的工具， eurysm（MA）的出现和消失率（统称为周转率）， 用作量化DR进展风险的生物标志物，沿着纵向分析 其他DR病变。可靠的基于图像的生物标志物的可用性将具有很高的阳性率， 积极影响DR护理的各个方面，包括筛查，监测进展， 药物发现和临床研究。 测量MA周转率和DR病变的纵向分析涉及两项工作， 紧张的步骤：仔细对齐当前和基线图像，并标记个人 病变如果完全由人工完成，此过程非常耗时且容易出错 评分员该项目的主要目标是通过自动化来克服这些限制， 纵向分析中涉及的两个步骤：精确的图像配准和病变 识别. 我们设计并开发了一个原型工具， 图像（即使有多个病变变化），并有效地检测和定位DR le， Ssions。这个完全自动化的工具可以在云上工作，以近乎恒定的速度产生结果。 时间（对于大型数据集），还为临床医生提供直观的可视化工具， 有效监测DR进展。商业化准备试点项目（CRP） 旨在为EyeMark制定监管策略和市场准入计划， 使其能够在美国市场推出并促进商业成功。

Abstract In this project, we present EyeMark, a system with advanced longitudinal image anal- ysis tools for automated computation of biomarkers for diabetic retinopathy (DR) using retinal fundus images. Specifically, we have developed tools for computation of microan- eurysm (MA) appearance and disappearance rates (jointly known as turnover rates) for use as a biomarker in quantifying DR progression risk along with longitudinal analysis of other DR lesions. The availability of a reliable image-based biomarker will have high pos- itive influence on various aspects of DR care, including screening, monitoring progres- sion, drug discovery and clinical research. Measuring MA turnover and longitudinal analysis of DR lesions involves two labor in- tensive steps: careful alignment of current and baseline images, and marking of individual lesions. This process is very time consuming and prone to error, if done entirely by human graders. The primary goal of this project is to overcome these limitations by automating both the steps involved in longitudinal analysis: accurate image registration, and lesion identification. We have designed and developed a prototype tool that robustly registers longitudinal images (even with multiple lesion changes) and effectively detects and localizes DR le- sions. This fully automated tool can work on the cloud to produces results in near constant time (for large datasets), and also provide intuitive visualization tools for clinicians to more effectively monitor DR progression. This commercialization readiness pilot (CRP) project is intended to develop a regulatory strategy and a market access plan for EyeMark to enable its introduction in the US market and foster commercial success.